• Ethos Precision Medicine Umbrella Study for Hemangiosarcoma (Ethos-PUSH)

    Currently Enrolling

    Ethos Discovery now seeks to deliver a highly advanced clinical trial program investigating the use of novel drugs for the treatment of Hemangiosarcoma (HSA) with the goal of curing this aggressive cancer. This study will ask if drugs specifically matched to the genomic subtypes of patients with HSA will result in improved outcomes.

    Study Details
  • Survey of Endogenous Procalcitonin in Sepsis with Individual Sequencing (SEPSIS)

    Currently Enrolling

    The goal of this study is to evaluate changes in procalcitonin levels over time in canine patients surgically treated for sepsis secondary to an abdominal cause (i.e. ruptured intestine). Additional blood sample collection will also be performed to investigate for possible novel markers for sepsis using next generation sequencing for the future development of diagnostic test.

    Study Details
  • Sorafenib for the Treatment of Solid Tumors in Dogs

    No Longer Enrolling

    We have previously reported on the tolerability and hints of clinical activity of Sorafenib in dogs with cancer. This background provides a rationale for the further study of Sorafenib in dogs with cancer. In this study we seek to define an optimal dosing schedule for Sorafenib and will assess its tolerability and activity in dogs with solid tumors.

    Study Details
  • Rapamycin for the Treatment of Hemangiosarcoma in Dogs

    No Longer Enrolling

    Based on its reported tolerability in dogs (alone and in combination with chemotherapy) this study will ask whether Rapamycin may improve treatment outcomes for dogs with hemangiosarcoma, and more precisely, to understand the hemangiosarcoma genotypes which may most benefit from its use.

    Study Details